Anastrozole (Arimidex)

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Also Known As:

Arimidex; 2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile); Anastrazole; ICI D1033; ZD-1033; ZD1033; Zeneca ZD 1033; ZD 1033; 1,3-Benzenediacetonitrile, alpha,alpha,alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-

Networked: 1277 relevant articles (202 outcomes, 492 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Cuzick, Jack: 48 articles (01/2022 - 01/2003)
2.	Dowsett, Mitch: 44 articles (01/2022 - 02/2002)
3.	Howell, Anthony: 39 articles (07/2021 - 04/2002)
4.	Buzdar, Aman U: 28 articles (01/2021 - 06/2002)
5.	Sestak, Ivana: 25 articles (01/2022 - 09/2008)
6.	Ingle, James N: 24 articles (01/2022 - 08/2002)
7.	Ellis, Matthew J: 23 articles (10/2021 - 12/2006)
8.	Goss, Paul E: 17 articles (10/2021 - 08/2003)
9.	Gnant, Michael: 16 articles (01/2021 - 08/2005)
10.	Noguchi, Shinzaburo: 16 articles (05/2018 - 01/2003)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 12/01/2007 - "Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer." 03/01/2013 - "[Three patients with local recurrence of ER-positive breast cancer for whom anastrozole was clinically effective]." 03/01/1996 - "Anastrozole is an effective and well tolerated treatment for postmenopausal patients with advanced breast cancer. " 04/01/2017 - "Anastrozole has shown promising results in the adjuvant treatment of early-stage breast cancer in postmenopausal women. " 01/01/1997 - "The future potential of anastrozole is currently being investigated in a programme of clinical trials in postmenopausal women, including first-line treatment of advanced disease and as an adjuvant treatment for early breast cancer."
2.	Neoplasms (Cancer) 01/01/2018 - "Compared with anastrozole alone, anastrozole/UFT did not achieve significantly higher RR [39.3% (90% CI 23.8-56.5%) vs 14.3% (90% CI 5.0-29.8%); p = 0.0683, Fisher's exact test], but produced significantly greater tumor shrinkage (mean tumor reduction rate 31.0 vs. 14.2%; p = 0.0181, unpaired t-test). " 08/01/2008 - "Anastrozole was effective for the control of tumor growth and her symptoms. " 07/01/2011 - "In this study we set out to investigate the significance of intrinsic subtypes within a group of ER+ve breast cancers treated with neoadjuvant anastrozole. " 12/01/2003 - "Phase II trial of anastrozole in women with asymptomatic müllerian cancer." 10/01/2022 - "In Model 2, blood components were treated with Anastrozole, then exposed to cancer cells, modelling circulatory effects in the vasculature. "
3.	Neoplasm Metastasis (Metastasis) 01/01/2021 - "After two years of anastrozole treatment (1mg/day), there was regression of all cutaneous lesions and stabilization of bone metastasis. " 01/01/2020 - "Finally, in two independent clinical cohorts of ER positive BC, we find a strong association between high expression of PLK1 and a shorter metastases-free survival and poor response to anastrozole. " 12/24/2014 - "She had been started on anastrozole in May 2013 for bony metastases, detected on a bone scan. " 08/06/2013 - "Normal weight patients with additional 3 years of anastrozole halved their risk of disease recurrence (disease-free survival (DFS) HR 0.48; P=0.02) and death (HR 0.45; P=0.06) and had only a fifth of the risk of distant metastases (HR 0.22; P=0.05) compared with normal weight patients without any further treatment. " 12/01/2003 - "In patients with or without visceral metastases, second-line treatment with anastrozole resulted in a CB rate of 31.4 and 51.8%, respectively, compared with 31.9 and 47.1%, respectively, for those treated with MA. "
4.	Endometriosis 01/01/2017 - "One pilot study evaluated the efficacy of vaginal anastrozole in women with rectovaginal endometriosis. " 06/01/2023 - "A novel anastrozole intravaginal ring for endometriosis: Pharmacokinetic characteristics and mucosal irritation." 01/01/2021 - "Dosing anastrozole for 6 months, starting one month before CS of endometriosis, reduces significantly the painful symptoms and delays recurrence, but has no other significant advantages over the single insertion of LNG-IUD (Mirena®) during the same time. " 01/01/2021 - "After CS for endometriosis, a reduction of ultrasound findings of endometriomas and long-term recurrence occurred, with or without anastrozole. " 01/01/2021 - "Anastrozole 1 mg/day and/or only Mirena® for 6 months; CS (ovarian and fertility-sparing) or TUGPA of endometriomas one month after starting medical treatment. "
5.	Noninfiltrating Intraductal Carcinoma (DCIS) 09/06/2003 - "Anastrozole for ductal carcinoma in situ." 11/01/2020 - "Here, we report blinded long-term follow-up results for the IBIS-II trial, which compared anastrozole with placebo, with the objective of determining the efficacy of anastrozole for preventing breast cancer (both invasive and ductal carcinoma in situ) in the post-treatment period. " 01/01/2018 - "Here, we evaluate adherence to anastrozole in the International Breast Cancer Intervention Study (IBIS)-II prevention and ductal carcinoma in situ (DCIS) trials, and its association with early symptoms. " 07/08/2014 - "The IBIS-II trial investigated breast cancer prevention with anastrazole in two cohorts: women with increased risk (Prevention), and women treated for ductal carcinoma in situ (DCIS). " 01/01/2003 - "The potential role of anastrozole in the neoadjuvant setting, the management of DCIS, premenopausal breast cancer and breast cancer prevention is currently being investigated."

Related Drugs and Biologics

1.	Tamoxifen
2.	Letrozole (Femara)
3.	Hormones (Hormone)
4.	Aromatase Inhibitors
5.	Anastrozole (Arimidex)
6.	exemestane (Aromasin)
7.	Fulvestrant (Faslodex)
8.	Estrogen Receptors
9.	Aromatase (CYP19)
10.	Estrogens (Estrogen)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Chemoprevention
5.	Segmental Mastectomy (Lumpectomy)